Acute toxicity of ibogaine and noribogaine

Medicina

Volumn 44, Issue 12, 2008, Pages 984-988

  Kubiliene, Asta ^a   Marksiene, Rura ^a   Kazlauskas, Saulius ^a   Sadauskiene, Ilona ^a   Ražukas, Almantas ^b   Ivanov, Leonid ^a  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^b INSTITUTE OF AGRICULTURE   (Lithuania)

Author keywords

Ibogaine; Median lethal dose; Mice; Noribogaine; Toxicity

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; IBOGAINE; NORIBOGAINE; PSYCHEDELIC AGENT;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; DRUG EFFECT; EVALUATION; LD 50; MOUSE; STOMACH;

ANIMALS; BEHAVIOR, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; IBOGAINE; LETHAL DOSE 50; MICE; STOMACH;

EID: 59149093332     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina44120123     Document Type: Article

References (19)

1. Dao-Yao He, Nancy N, McGough H, Ravindranathan A, Jeanblanc J, Janak PH, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 2005;3:619-28.
2. Kazlauskas S, Kontrimavičiute V, Sveikata A. Ibogaine - the substance for treatment of toxicomania. Neurochemical and pharmacological action. Medicina (Kaunas) 2004;3:216-9.
3. Lotsof HS. Ibogaine in the treatment of chemical dependency disorders: clinical perspectives. Bull MAPS 1995;5:16-27.
4. Sisko B. Interrupting drug dependency with ibogaine: a summary of four case histories. Bull MAPS 1993;4:15-24.
5. Popik P, Layer RT, Fossom L, Benveniste M, Getter-Douglas B, Witkin JM, et al. NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J Pharmacol Exp Ther 1995;275:753.
6. Pearl SM, Herrickdavis K, Teitler M, Glick SD. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res 1995;675:342-4.
7. Pearl SM, Hough LB, Boyd DL, Glick SD. Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Pharmacol Biochem Behav 1997;57(4):809-15.
8. Glick SD, Pearl SM, Cai J, Maisonneuve IM. Ibogaine-like effects of noribogaine in rats. Brain Res 1996;713:294-7.
9. Layer RT, Skolnick P, Bertha CM, Kuehne ME, Popik P. Modification of the expression of morphine dependence by ibogaine derivatives: relation to NMDA antagonist actions. Eur J Pharmacol 1996;309:159-65.
10. Kontrimavičiute V, Larroque M, Briedis V, Margout D, Bressolle F. Quantitation of ibogaine and 12-hydroxyibogamine in human plasma by liquid chromatography with fluorimetric detection. J Chromatogr B 2005;822(1-2):285-93.
11. Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its o-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001;297:531-9.
12. Jing-Hui L, Marsh RE. LD50 determination of zinc phosphide toxicity for house mice and albino laboratory mice. In Proceedings of the 13th Vertebrate Pest Conference. University of California; 1988. p. 91-4.
13. Hough LB, Pearl SM, Glick SD. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sciences 1996;58:119-22.
14. Delourme-Houde J. Contribution a l'etude de l'iboga (Tabernanthe Iboga H. Bn). Ann Pharm Fr 1946;4:30-6.
15. Sanchez-Ramos J, Mash D. Ibogaine research update: phase I human study. Bull MAPS 1994;4:11.
16. Xu Z, Chang LW, Slikker WJr, Ali SF, Rountree RL, Scallet AC. A dose-response study of ibogaine-induced neuropathology in the rat cerebellum. Toxicol Sci 2000;57:95-101.
17. Molinari HH, Maisonneuve IM, Glick SD. Dose dependence of ibogaine neurotoxicity. Soc Neurosci Abstr 1994;20:1236.
18. Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 1992; 31:497-500.
19. O'Hearn E, Molliver ME. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after ibogaine or harmaline. Neuroscience 1993;55:303-10.